Compare IDEXX Laboratories, Inc. (IDXX) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Payoneer Global Inc — how do they compare? IDEXX Laboratories, Inc. trades at $519.96 (market cap $40.43B), while Payoneer Global Inc trades at $7.15 (market cap $2.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 16.6× Payoneer Global Inc's market cap, and Payoneer Global Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Payoneer Global Inc for 61 Days on average.
| IDXX | PAYO | |
|---|---|---|
Market Cap | $40.43B | $2.43B |
Volume | 692,164 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $766.68 | $7.18 |
52-Week Low | $504.70 | $4.27 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | $2.17B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $519.87, up 2.61% on the day, with a bearish technical signal from moving averages but strong fundamentals including a 25.03% net income margin and consistent earnings beats. Revenue grew to $4.3B in 2025, and the company recently acquired CoVetAI to enhance veterinary workflow intelligence, signaling strategic expansion.
The stock's outlook is supported by robust profitability and analyst consensus, but faces headwinds from technical weakness and potential market volatility. With a $665 price target implying significant upside, the primary risks include competitive pressures and execution of growth initiatives amid economic uncertainties.
Payoneer Global (PAYO) trades at $7.15, down slightly by 0.14% with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and the company's agreement to be acquired by Nuvei announced in June 2026. Analyst sentiment remains positive with 60% buy ratings despite recent earnings volatility.
The acquisition by Nuvei creates near-term upside potential, but execution risks and margin compression pose challenges. Revenue growth remains solid at 15% volume growth year-over-year, though net income margin has declined from 16.8% in 2024 to 5.8% projected for 2026. The stock's valuation at 51x P/E appears stretched relative to earnings growth, suggesting cautious optimism is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
